| pubmed-article:12620274 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12620274 | lifeskim:mentions | umls-concept:C0013557 | lld:lifeskim |
| pubmed-article:12620274 | lifeskim:mentions | umls-concept:C0337812 | lld:lifeskim |
| pubmed-article:12620274 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
| pubmed-article:12620274 | lifeskim:mentions | umls-concept:C0597535 | lld:lifeskim |
| pubmed-article:12620274 | lifeskim:mentions | umls-concept:C0016640 | lld:lifeskim |
| pubmed-article:12620274 | lifeskim:mentions | umls-concept:C1547707 | lld:lifeskim |
| pubmed-article:12620274 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:12620274 | lifeskim:mentions | umls-concept:C0439234 | lld:lifeskim |
| pubmed-article:12620274 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:12620274 | pubmed:dateCreated | 2003-3-6 | lld:pubmed |
| pubmed-article:12620274 | pubmed:abstractText | The establishment of the Norwegian Fractionation Project (Project) was of major importance in preserving national self-sufficiency when plasma, cryoprecipitate and small batch factor IX-concentrates were replaced by virus inactivated products in the last part of the 1980s. Fractionation was performed abroad by contract with Octapharma after tenders on the European market. All Norwegian blood banks (>50) participated in the Project. Total yearly production was 50-60 tons of mainly recovered plasma. From 1993 solvent detergent (SD) treated plasma has replaced other plasma for transfusion. The blood banks paid for the fractionation and/or viral inactivation process, while the plasma remained the property of the blood banks and the final products were returned to the blood banks. The Project sold surplus products to other Norwegian blood banks and the majority of the coagulation factor concentrates to The Institute of Haemophilia and Rikshospitalet University Hospital. Both plasma and blood bank quality was improved by the Project. Clinical experience with the products has been satisfactory and self-sufficiency has been achieved for all major plasma proteins and SD plasma, but a surplus exceeding 3 years consumption of albumin has accumulated due to decreasing clinical use.The Project has secured high yields of the fractionated products and the net income from the produced products is NOK 1115 (140 Euros or US dollars) per litre plasma. An increasing surplus of albumin and the possibility of significant sales abroad of currently not fractionated IVIgG, could lead to a reorganisation of the Project from that of a co-ordinator to a national plasma handling unit. This unit could buy the plasma from the blood banks and have the plasma fractionated by contract after tender, before selling the products back for cost recovery. The small blood banks could produce plasma for products for the Norwegian market, while surplus products from the larger blood banks which are certified for delivery of plasma for fractionation of products to be consumed in the European Community, could be sold on the international market. | lld:pubmed |
| pubmed-article:12620274 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12620274 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12620274 | pubmed:citationSubset | T | lld:pubmed |
| pubmed-article:12620274 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12620274 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:12620274 | pubmed:issn | 1473-0502 | lld:pubmed |
| pubmed-article:12620274 | pubmed:author | pubmed-author:SolheimB GBG | lld:pubmed |
| pubmed-article:12620274 | pubmed:author | pubmed-author:SeghatchianJJ | lld:pubmed |
| pubmed-article:12620274 | pubmed:author | pubmed-author:FleslandOO | lld:pubmed |
| pubmed-article:12620274 | pubmed:copyrightInfo | Copyright 2003 Elsevier Science Ltd. | lld:pubmed |
| pubmed-article:12620274 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12620274 | pubmed:volume | 28 | lld:pubmed |
| pubmed-article:12620274 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12620274 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12620274 | pubmed:pagination | 93-100 | lld:pubmed |
| pubmed-article:12620274 | pubmed:dateRevised | 2006-6-7 | lld:pubmed |
| pubmed-article:12620274 | pubmed:meshHeading | pubmed-meshheading:12620274... | lld:pubmed |
| pubmed-article:12620274 | pubmed:meshHeading | pubmed-meshheading:12620274... | lld:pubmed |
| pubmed-article:12620274 | pubmed:meshHeading | pubmed-meshheading:12620274... | lld:pubmed |
| pubmed-article:12620274 | pubmed:meshHeading | pubmed-meshheading:12620274... | lld:pubmed |
| pubmed-article:12620274 | pubmed:meshHeading | pubmed-meshheading:12620274... | lld:pubmed |
| pubmed-article:12620274 | pubmed:meshHeading | pubmed-meshheading:12620274... | lld:pubmed |
| pubmed-article:12620274 | pubmed:meshHeading | pubmed-meshheading:12620274... | lld:pubmed |
| pubmed-article:12620274 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12620274 | pubmed:articleTitle | The Norwegian Plasma Fractionation Project--a 12 year clinical and economic success story. | lld:pubmed |
| pubmed-article:12620274 | pubmed:affiliation | Blood Bank, Baerum Hospital, N-1306 Barum, Norway. oystein.flesland@baerum-sykehus.no | lld:pubmed |
| pubmed-article:12620274 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12620274 | lld:pubmed |
